Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up – Here’s Why

Telix Pharmaceuticals Limited (NASDAQ:TLX) shares gapped up before the market opened on Wednesday . The stock had previously closed at $10.21, but opened at $10.81. Telix Pharmaceuticals shares last traded at $10.9050, with a volume of 56,813 shares.

Analysts Set New Price Targets

Several analysts have weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a report on Monday, April 13th. Wall Street Zen upgraded shares of Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, April 11th. Citigroup increased their price objective on shares of Telix Pharmaceuticals from $22.00 to $22.50 and gave the company a “buy” rating in a research note on Tuesday, February 24th. Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Monday, April 20th. Finally, Wedbush restated an “outperform” rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a report on Monday, April 13th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Telix Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $21.12.

Telix Pharmaceuticals Price Performance

The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. The firm’s 50 day moving average is $10.12 and its two-hundred day moving average is $8.73.

Insider Activity at Telix Pharmaceuticals

In other news, CEO Christian Behrenbruch acquired 33,435 shares of the business’s stock in a transaction dated Wednesday, April 29th. The stock was acquired at an average price of $14.87 per share, with a total value of $497,178.45. Following the completion of the transaction, the chief executive officer directly owned 20,742,935 shares in the company, valued at approximately $308,447,443.45. This represents a 0.16% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

Institutional Trading of Telix Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Rhumbline Advisers grew its stake in Telix Pharmaceuticals by 117.3% in the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after acquiring an additional 1,392 shares during the period. Bank of America Corp DE raised its holdings in Telix Pharmaceuticals by 523.8% in the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after acquiring an additional 8,423 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Telix Pharmaceuticals during the 4th quarter worth $89,000. XY Capital Ltd purchased a new position in shares of Telix Pharmaceuticals during the 1st quarter worth $120,000. Finally, IHT Wealth Management LLC acquired a new stake in shares of Telix Pharmaceuticals during the second quarter worth $213,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.